Analyst Recommendation Trends
Wall Street analyst consensus for ODTX over the last few months:
Latest ODTX News
Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Odyssey Therapeutics, Inc. (ODTX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:45 AM EDTCompany ParticipantsGary Glick -...
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team are scheduled to present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23 at 11
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
On August 4, Odyssey Therapeutics (NASDAQ:ODTX) reported its second-quarter financial results and gave investors a fresh look at where its lead autoimmune drug candidate stands. The clinical-stage biopharmaceutical company said it closed the quarter with $433.1 million in cash, enough to keep the lights on well into 2028, while its RIPK2 inhibitor OD-001 moves toward […]